Synthesis

A scoping review of 21 studies covering roughly 681,000 participants finds people with opioid use disorder have palliative care needs equivalent to the general population but face fragmented care, unmet pain management and stigma-driven access barriers.

A scoping review of 15 international Hospital-at-Home admission-avoidance models finds just four used a validated frailty measure, and communication practice between professionals, patients and carers varied widely.

A multidisciplinary clinical consensus sets out age-adjusted opioid selection, dosing and route-of-administration standards for treating chronic pain safely in older adults.

A consensus of 16 international experts concludes that delivery and implementation capacity — not the underlying evidence for high-dose, high-intensity rehabilitation — is the primary barrier to delivering it, and names home- and community-based hybrid delivery as essential to closing the gap.

A scoping review of 18 studies covering over 5,000 patients finds outpatient parenteral antimicrobial therapy readmission risk tracks whether a competent team member performs the initial patient assessment, not how many quality indicators a service reports.

A systematic review of four randomised trials finds telerehabilitation is non-inferior to conventional in-person stroke rehabilitation for arm motor recovery only in the one trial that matched therapy dose between arms, with smaller, non-dose-matched trials showing mixed results.

A realist review of 126 studies identifies six mechanisms through which mobile health interventions improve home-based palliative care outcomes, and cautions that mHealth must be tailored to local infrastructure and technology competence rather than treated as a substitute for workforce capacity.

A mixed-methods systematic review of 34 studies finds rural palliative care access breaks down cumulatively across recognition, entry, reach and continuity stages, with distance, workforce shortages and weak specialist-generalist referral links driving the biggest barrier.

This week's evidence answers a question earlier weeks left open: not whether earlier, community-facing care reduces avoidable hospital use, but what makes that model actually work — and a national dataset supplies the clearest quantified evidence yet that the workforce needed to deliver it is under strain.

A narrative review of 40 studies from 2000 to 2025 finds that multicomponent advance care planning interventions combining training, decision aids, systems prompts and dedicated consultations most consistently raise completion rates, while single-component reminders alone perform weaker.

This week's evidence reinforces a pattern now confirmed for over a month — earlier, community-facing recognition and disposition decisions cut avoidable hospital use more reliably than downstream specialist capacity — while a national workforce survey is a reminder that the generalist staff needed to deliver 'earlier' care are themselves under real strain.

A scoping review of 70 studies identifies 13 barriers, 13 facilitators and 27 interventions relevant to advance care planning among people experiencing housing instability, poverty, racialised identity, serious mental illness or substance use.

A UK policy scoping review finds current Hospital at Home implementation criteria risk excluding people with dementia who lack digital proficiency or carer support, even though such schemes could otherwise reduce inequalities for this group.

This week's evidence converges on a single reframing: as care shifts toward home-based and remote delivery, digital proficiency and carer capacity — not clinical eligibility — increasingly determine who benefits, while deliberate workforce deployment, not new treatment or technology, is this period's clearest lever for improving outcomes.

National data showing the oldest patients face the longest emergency department waits converges with a fourth consecutive week of clinical evidence pointing to early identification as the dominant lever, while several of this week's largest measured gains came from low-cost structured protocols rather than new technology.

A new position paper proposes a standardised composite outcome, MACE-Cog, to address widespread inconsistency and incompleteness in how cognitive decline is measured and reported after stroke and cardiac interventions.

A PROSPERO-registered systematic review identifies the structural and process determinants that distinguish nursing homes that implement advance care planning well from those that do not.

A systematic review of 12 randomised trials finds app- and web-based telerehabilitation performs comparably to centre-based cardiac rehabilitation after acute coronary syndrome or revascularisation, with gains in adherence and quality of life.

A critical review maps five national crisis-response models for older people onto shared commissioning design principles, offering a common benchmark for services usually assessed in isolation.

This week's evidence shows that assessment and identification at first contact, not treatment availability, determines whether frail, cognitively impaired and dying patients reach the right pathway, while national data confirms the capacity cost of getting it wrong.

An integrative review of 33 studies finds telehealth-supported home palliative care improves access and symptom-management continuity, but success depends on digital literacy, caregiver burden and organisational readiness.

A systematic review of 36 studies finds such variation in terminology, teams and assessment tools that no single study could describe a full geriatric rehabilitation pathway holistically.

A systematic review and meta-analysis finds weak evidence behind reablement-based discharge-to-assess — the model much of the NHS relies on — as this week's wider evidence converges on workforce capacity, documentation continuity and referral screening as the binding constraint on better frailty, palliative and rehabilitation care.

This week's evidence and national policy commentary converge: identifying who is structurally at risk, and redesigning access around that, is where the largest near-term gains in value-added time sit — not new clinical treatment.